Fecal microbiota transplantation in patients with metabolic syndrome and obesity: A randomized controlled trial

Imagem de Miniatura
Arquivos
art_PONTE NETO_Fecal_microbiota_transplantation_in_patients_with_metabolic_syndrome_2023.PDF (1.44 MB)
Citações na Scopus
Tipo de produção
article
Data de publicação
2023
DOI
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BAISHIDENG PUBLISHING GROUP INC
Autores
CLEMENTE, Aniele Cristine Ott
NUNES, Gabriel Cairo
MOREIRA, Luana
SPARVOLI, Luiz Gustavo
CORTEZ, Ramon
TADDEI, Carla Romano
Citação
WORLD JOURNAL OF CLINICAL CASES, v.11, n.19, p.4612-4624, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BACKGROUNDMetabolic syndrome is a multifactorial disease, and the gut microbiota may play a role in its pathogenesis. Obesity, especially abdominal obesity, is associated with insulin resistance, often increasing the risk of type two diabetes mellitus, vascular endothelial dysfunction, an abnormal lipid profile, hypertension, and vascular inflammation, all of which promote the development of atherosclerotic cardiovascular disease.AIMTo evaluate the outcomes of fecal microbiota transplantation (FMT) in patients with metabolic syndrome.METHODSThis was a randomized, single-blind placebo-controlled trial comparing FMT and a sham procedure in patients with metabolic syndrome. We selected 32 female patients, who were divided into eight groups of four patients each. All of the patients were submitted to upper gastrointestinal endoscopy. In each group, two patients were randomly allocated to undergo FMT, and the other two patients received saline infusion. The patients were followed for one year after the procedures, during which time anthropometric, bioimpedance, and biochemical data were collected. The patients also had periodic consultations with a nutritionist and an endocrinologist. The primary end point was a change in the gut microbiota.RESULTSThere was evidence of a postprocedural change in microbiota composition in the patients who underwent FMT in relation to that observed in those who underwent the sham procedure. However, we found no difference between the two groups in terms of the clinical parameters evaluated.CONCLUSIONThere were no significant differences in biochemical or anthropometric parameters, between the two groups evaluated. Nevertheless, there were significant postprocedural differences in the microbiota composition between the placebo group. To date, clinical outcomes related to FMT remain uncertain.
Palavras-chave
Fecal microbiota transplantation, Metabolic syndrome, Obesity, Endoscopy, Diabetes mellitus, Endocrinology
URI
https://observatorio.fm.usp.br/handle/OPI/56323
Referências
  1. Alberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464-5491.2006.01858.x
  2. Allegretti JR, 2020, CLIN GASTROENTEROL H, V18, P855, DOI 10.1016/j.cgh.2019.07.006
  3. Bäckhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101
  4. Bagdasarian N, 2015, JAMA-J AM MED ASSOC, V313, P398, DOI 10.1001/jama.2014.17103
  5. Cammarota G, 2014, J CLIN GASTROENTEROL, V48, P693, DOI 10.1097/MCG.0000000000000046
  6. CHAO A, 1984, SCAND J STAT, V11, P265
  7. Chu ND, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170922
  8. Clarke JTR, 2005, METABOLIC SYNDROME T, P28
  9. Costello SP, 2017, ALIMENT PHARM THER, V46, P213, DOI 10.1111/apt.14173
  10. Dao MC, 2016, GUT, V65, P426, DOI 10.1136/gutjnl-2014-308778
  11. Davidovics ZH, 2019, J PEDIATR GASTR NUTR, V68, P130, DOI 10.1097/MPG.0000000000002205
  12. Druart C, 2014, LIPIDS, V49, P397, DOI 10.1007/s11745-014-3881-z
  13. Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7
  14. Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381
  15. Forslund K, 2015, NATURE, V528, P262, DOI 10.1038/nature15766
  16. GBD 2015 Obesity Collaborators, 2017, N Engl J Med, V377, P13, DOI 10.1056/NEJMoa1614362
  17. Grundy SM, 2007, J CLIN ENDOCR METAB, V92, P399, DOI 10.1210/jc.2006-0513
  18. Kittelson JM, 2011, J BIOPHARM STAT, V859
  19. Kootte RS, 2017, CELL METAB, V26, P611, DOI 10.1016/j.cmet.2017.09.008
  20. Kozich JJ, 2013, APPL ENVIRON MICROB, V79, P5112, DOI 10.1128/AEM.01043-13
  21. Le Chatelier E, 2013, NATURE, V500, P541, DOI 10.1038/nature12506
  22. Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102
  23. Lindsay Robert S, 2004, Curr Diab Rep, V4, P63, DOI 10.1007/s11892-004-0013-9
  24. Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005
  25. Lozupone CA, 2012, NATURE, V489, P220, DOI 10.1038/nature11550
  26. Navas-Molina JA, 2013, METHOD ENZYMOL, V531, P371, DOI 10.1016/B978-0-12-407863-5.00019-8
  27. Nishida A, 2018, CLIN J GASTROENTEROL, V11, P1, DOI 10.1007/s12328-017-0813-5
  28. Plovier H, 2017, NAT MED, V23, P107, DOI 10.1038/nm.4236
  29. Proença IM, 2020, NUTR RES, V83, P1, DOI 10.1016/j.nutres.2020.06.018
  30. Pylro VS, 2014, J MICROBIOL METH, V107, P30, DOI 10.1016/j.mimet.2014.08.018
  31. Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219
  32. Reaven G M, 1997, Nutrition, V13, P66
  33. Reunanen J, 2015, APPL ENVIRON MICROB, V81, P3655, DOI 10.1128/AEM.04050-14
  34. Saklayen MG, 2018, CURR HYPERTENS REP, V20, DOI 10.1007/s11906-018-0812-z
  35. Sasson AN, 2021, LANCET GASTROENTEROL, V6, P754, DOI 10.1016/S2468-1253(21)00097-2
  36. Shah AY, 2020, AM J GASTROENTEROL, V115, P814, DOI 10.14309/ajg.0000000000000604
  37. SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x
  38. Shen NT, 2017, GASTROENTEROLOGY, V152, P1889, DOI 10.1053/j.gastro.2017.02.003
  39. Shin NR, 2014, GUT, V63, P727, DOI 10.1136/gutjnl-2012-303839
  40. Smits LP, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008342
  41. Strauss RS, 2001, JAMA-J AM MED ASSOC, V286, P2845, DOI 10.1001/jama.286.22.2845
  42. Vallianou NG, 2019, HORM-INT J ENDOCRINO, V18, P141, DOI 10.1007/s42000-019-00093-w
  43. van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI [10.1056/NEJMoa1205037, 10.1056/NEJMc1303919]
  44. Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031
  45. Zhang Q, 2020, DIABET METAB SYND OB, V13, P5003, DOI 10.2147/DMSO.S286430
  46. Zhang ZX, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102291

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/18
Artigos e Materiais de Revistas Científicas - LIM/35